A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability
- 22 October 2021
- journal article
- research article
- Published by Wiley in Angewandte Chemie
- Vol. 61 (33), e202109500
- https://doi.org/10.1002/anie.202109500
Abstract
Currently, the broad use of monovalent aptamers in oncology faces challenges, including insufficient recognition and internalization caused by finite unitary receptors, as well as confined recognition spectrum. Herein, we describe the development of a dual-targeting circular aptamer (DTCA) that can recognize two different biomarkers on living cells to augment aptamer-receptor interactions, thus allowing the enhanced recognition event to occur. This improvement not only boosts binding and internalization abilities, but also expands the recognition spectrum for different leukemia cells. Moreover, the stability of DTCA in serum can be significantly improved by an enzyme-promoted terminal ligation strategy. The chemical incorporation of 5-fluorodeoxyuridine into DTCA resulted in a pharmaceutically functional aptamer that exhibited excellent selectivity, as demonstrated by its high cytotoxicity against target cancer cells, but not to normal cells. The superiority of our newly developed strategy was further highlighted by its precise tumor imaging capability.Funding Information
- National Key Research and Development Program of China (2018YFA0902300)
- National Natural Science Foundation of China (21827811, 91753109)
This publication has 28 references indexed in Scilit:
- Strategies and challenges for the next generation of antibody–drug conjugatesNature Reviews Drug Discovery, 2017
- Antibody-drug conjugates—an emerging class of cancer treatmentBritish Journal of Cancer, 2016
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyCancer Cell, 2016
- Aptamer–Drug ConjugatesBioconjugate Chemistry, 2015
- DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue RecognitionTheranostics, 2015
- Self‐Assembled Aptamer‐Based Drug Carriers for Bispecific Cytotoxicity to Cancer CellsChemistry – An Asian Journal, 2012
- Development of DNA aptamers using Cell-SELEXNature Protocols, 2010
- Cell-Specific Aptamer Probes for Membrane Protein Elucidation in Cancer CellsJournal of Proteome Research, 2008
- Optimization and Modifications of Aptamers Selected from Live Cancer Cell LinesChemBioChem, 2007
- BiTEs: bispecific antibody constructs with unique anti-tumor activityDrug Discovery Today, 2005